Published third-party EST trials
| Study . | Year . | Target . | N . | Serious adverse events . | Clinical results . |
|---|---|---|---|---|---|
| 94 | 2007 | EBV | 33 | None | 52% CR/PR |
| 81,95 | 2010, 2012 | EBV | 5 | None | 4/5 CR |
| 97 | 2013 | CMV, EBV, Adv | 50 | 8 cases GVHD (2 de novo) | 74% CR/PR |
| 96 | 2017 | CMV, EBV, Adv, BK, HHV6 | 38 | 2 cases of de novo GVHD (grade 1) | 92% CR/PR |
| 92 | 2018 | CMV, EBV, Adv | 30 | 2 cases of de novo GVHD | 93% CR/PR |
| 90 | 2020 | EBV | 46 | None | 68% CR/PR (BMT) 54% CR/PR (SOT) |
| Study . | Year . | Target . | N . | Serious adverse events . | Clinical results . |
|---|---|---|---|---|---|
| 94 | 2007 | EBV | 33 | None | 52% CR/PR |
| 81,95 | 2010, 2012 | EBV | 5 | None | 4/5 CR |
| 97 | 2013 | CMV, EBV, Adv | 50 | 8 cases GVHD (2 de novo) | 74% CR/PR |
| 96 | 2017 | CMV, EBV, Adv, BK, HHV6 | 38 | 2 cases of de novo GVHD (grade 1) | 92% CR/PR |
| 92 | 2018 | CMV, EBV, Adv | 30 | 2 cases of de novo GVHD | 93% CR/PR |
| 90 | 2020 | EBV | 46 | None | 68% CR/PR (BMT) 54% CR/PR (SOT) |
Shown are published results of prior clinical trials demonstrating safety of third-party ESTs.
Adv, adenovirus; BMT, bone marrow transplantation; CMV, cytomegalovirus; PR, partial response.